Success Metrics

Clinical Success Rate
22.2%

Based on 2 completed trials

Completion Rate
22%(2/9)
Active Trials
0(0%)
Results Posted
350%(7 trials)
Terminated
7(58%)

Phase Distribution

Ph phase_2
1
8%
Ph phase_1
11
92%

Phase Distribution

11

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
11(91.7%)
Phase 2Efficacy & side effects
1(8.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

16.7%

2 of 12 finished

Non-Completion Rate

83.3%

10 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(2)
Terminated(10)

Detailed Status

Terminated7
Withdrawn3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
22.2%
Most Advanced
Phase 2

Trials by Phase

Phase 111 (91.7%)
Phase 21 (8.3%)

Trials by Status

completed217%
terminated758%
withdrawn325%

Recent Activity

0 active trials
Showing 5 of 12
terminatedphase_1

Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

NCT04079738
completedphase_1

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

NCT02000934
terminatedphase_1

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

NCT02323113
terminatedphase_1

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

NCT03238651
withdrawnphase_1

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

NCT03338881
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04079738Phase 1

Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

Terminated
NCT02000934Phase 1

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

Completed
NCT02323113Phase 1

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Terminated
NCT03238651Phase 1

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

Terminated
NCT03338881Phase 1

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

Withdrawn
NCT03772288Phase 1

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

Withdrawn
NCT03123393Phase 2

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated
NCT03359733Phase 1

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Withdrawn
NCT02834247Phase 1

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

Terminated
NCT03357627Phase 1

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

Completed
NCT02954406Phase 1

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

Terminated
NCT02551055Phase 1

MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

Terminated

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12